<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614078</url>
  </required_header>
  <id_info>
    <org_study_id>PRCL-PoC</org_study_id>
    <nct_id>NCT03614078</nct_id>
  </id_info>
  <brief_title>A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PRCL Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PRCL Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in
      moderate to severe chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">July 8, 2019</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Following 12 weeks of treatment. The Psoriasis Area and Severity Index (PASI) scores the severity of disease on a scale from 0 to 72 (where a score of 72 indicates extreme disease severity). PASI 75 indicates 75% improvement from baseline to Week 12 in the Psoriasis Area and Severity Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Treatment Emergent Adverse Event</measure>
    <time_frame>Baseline up to week 18</time_frame>
    <description>Following 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC0-τ)</measure>
    <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
    <description>Steady state after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
    <description>Steady state after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Drug Concentration (Tmax)</measure>
    <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
    <description>Steady state after 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>PRCL-02 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRCL-02 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRCL-02</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>PRCL-02 Dose 1</arm_group_label>
    <arm_group_label>PRCL-02 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presents with moderate to severe psoriasis vulgaris based on:

               -  Chronic psoriasis vulgaris for at least 6 months

               -  Plaque psoriasis involving at least 10% body surface area (BSA)

               -  Psoriasis Area and Severity Index (PASI) total score of at least 12

          -  Have at least 2 evaluable plaques located in 2 different body regions. (Also for
             participants who elect to have plaques biopsied, should be suitable for a total of 4
             punch biopsies each, and one lesion, preferably on a region of the body that is not
             normally exposed (e.g., trunk), should be selected for biopsy)

          -  Have a Static Physician's Global Assessment (sPGA) score of greater than or equal to
             (≥)3

          -  Are candidates for systemic therapy

          -  Have a body mass index (BMI) within the range of 18 to 40 kilograms per square meter
             (kg/m2)

          -  Women who are of childbearing potential must agree to use 1 highly effective method of
             contraception, or a combination of 2 effective methods of contraception for the
             entirety of the study

          -  Women of non childbearing potential are defined as women who are:

               -  Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or
                  tubal ligation), congenital anomaly such as mullerian agenesis; or

               -  Post-menopausal, defined as either:

                    -  A woman at least 50 years of age with an intact uterus, not on hormone
                       therapy, who has had either: cessation of menses for at least 1 year; or at
                       least 6 months of spontaneous amenorrhea with a follicle stimulating hormone
                       greater than (&gt;)40 milli-international units per milliliter (mIU/mL); or

                    -  A woman 55 years or older not on hormone therapy, who has had at least 6
                       months of spontaneous amenorrhea; or

                    -  A woman at least 55 years of age with a diagnosis of menopause prior to
                       staring hormone replacement therapy

        Exclusion Criteria:

          -  Currently enrolled in any other clinical trial involving a study drug or device, or
             any other type of medical research judged not compatible with this study (Participants
             in the previous PRCL study (SMAD) will be allowed to be included in this study,
             provided that they meet all inclusion and none of the exclusion criteria)

          -  Participated in a clinical study within last 30 days

          -  Present with pustular, erythrodermic psoriasis, generalized pustular psoriasis, or
             acute guttate psoriasis

          -  Have current serious or unstable illnesses including hepatic, renal,
             gastroenterologic, respiratory, cardiovascular (including a history of ischemic or
             structural heart disease, conduction system disease or history of clinically
             significant arrhythmia), endocrinologic, neurologic, psychiatric, immunologic,
             hematologic, or dermatologic disease

          -  Have a history of clinically significant severe drug allergies or severe post
             treatment hypersensitivity reactions

          -  Have received inactivated vaccine within 4 weeks prior to dosing in this study, or a
             live vaccine within the last 3 months

          -  A history of clinically significant opportunistic infection (for example, invasive
             candidiasis or Pneumocystis pneumonia)

          -  Had symptomatic herpes zoster within last 3 months or other recent or ongoing
             infection

          -  Present with any of the following laboratory test results:

               -  Positive QuantiFERON®-tuberculosis test

               -  For women, positive serum pregnancy test

               -  Evidence of Human Immunodeficiency Virus (HIV) infection or are positive for HIV
                  antibodies

               -  Positive test for active hepatitis B

               -  Positive of anti-hepatitis C antibody with confirmed presence of hepatitis C
                  virus, or chronic liver disease

          -  Evidence of clinically significant hepatic or renal impairment

          -  Clinically significant ECG (electrocardiogram) abnormalities or personal or family
             history of heart disease, including:

               -  Confirmed corrected QT interval with Frederica's correction (QTcF) &gt;450
                  milliseconds (msec) for both men and women

               -  Specific bundle branch blocks, irregular rhythms, history of unexplained syncope,
                  or family history of unexplained death

          -  Are receiving any of the following therapies for psoriasis:

               -  Systemic retinoids within last 12 weeks

               -  Systemic psoriasis therapy, such as psoralen and ultraviolet A (PUVA) light
                  therapy, cyclosporine, corticosteroids, methotrexate, oral retinoids,
                  mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine, or
                  phototherapy (including ultraviolet B or self-treatment with tanning beds or
                  therapeutic sunbathing) within last 4 weeks

               -  Topical psoriasis treatment within last 2 weeks; or

               -  Any biologic agent within the following washout periods: 30 days for anti-tumor
                  necrosis factor (TNF) inhibitors, and 90 days for other agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>PRCL Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEffects</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carey-Wang - Dermatology &amp; Dermatologic Surgery Center</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxderm Dermatovenerologická ambulancia</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKINKLINIK Dermatovenerologická ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BeneDerma</name>
      <address>
        <city>Bratislava</city>
        <zip>841 02</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma therapy, spol.</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHS Dermatology</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SANARE - Dermatovenerologická ambulancia</name>
      <address>
        <city>Svidník</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska Clinical Hospital, Department of Dermatology and Venereology</name>
      <address>
        <city>Kiev</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC MK BLAGOMED, Department of Dermatology</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Dermatovenereology Clinical Hospital</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <results_first_submitted>March 9, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03614078/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03614078/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRCL-02 25 Milligrams (mg)</title>
          <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="P2">
          <title>PRCL-02 50 mg</title>
          <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
Placebo: Oral tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Did Not Return for Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>High Neutrophils</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Did Not Meet Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exacerbation of Psoriasis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dizziness and Rash</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>PRCL-02 25 Milligrams (mg)</title>
          <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="B2">
          <title>PRCL-02 50 mg</title>
          <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
Placebo: Oral tablets</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement</title>
        <description>Following 12 weeks of treatment. The Psoriasis Area and Severity Index (PASI) scores the severity of disease on a scale from 0 to 72 (where a score of 72 indicates extreme disease severity). PASI 75 indicates 75% improvement from baseline to Week 12 in the Psoriasis Area and Severity Index</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>PRCL-02 25 Milligrams (mg)</title>
            <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O2">
            <title>PRCL-02 50 mg</title>
            <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
Placebo: Oral tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement</title>
          <description>Following 12 weeks of treatment. The Psoriasis Area and Severity Index (PASI) scores the severity of disease on a scale from 0 to 72 (where a score of 72 indicates extreme disease severity). PASI 75 indicates 75% improvement from baseline to Week 12 in the Psoriasis Area and Severity Index</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Treatment Emergent Adverse Event</title>
        <description>Following 12 weeks of treatment</description>
        <time_frame>Baseline up to week 18</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRCL-02 25 Milligrams (mg)</title>
            <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O2">
            <title>PRCL-02 50 mg</title>
            <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
Placebo: Oral tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Treatment Emergent Adverse Event</title>
          <description>Following 12 weeks of treatment</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve (AUC0-τ)</title>
        <description>Steady state after 12 weeks of treatment</description>
        <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
        <population>Pharmacokinetic (PK) evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>PRCL-02 25 Milligrams (mg)</title>
            <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O2">
            <title>PRCL-02 50 mg</title>
            <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve (AUC0-τ)</title>
          <description>Steady state after 12 weeks of treatment</description>
          <population>Pharmacokinetic (PK) evaluable</population>
          <units>h*mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165000" spread="627"/>
                    <measurement group_id="O2" value="439000" spread="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax)</title>
        <description>Steady state after 12 weeks of treatment</description>
        <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
        <population>Pharmacokinetic (PK) evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>PRCL-02 25 Milligrams (mg)</title>
            <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O2">
            <title>PRCL-02 50 mg</title>
            <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax)</title>
          <description>Steady state after 12 weeks of treatment</description>
          <population>Pharmacokinetic (PK) evaluable</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984" spread="200"/>
                    <measurement group_id="O2" value="2220" spread="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Drug Concentration (Tmax)</title>
        <description>Steady state after 12 weeks of treatment</description>
        <time_frame>Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84</time_frame>
        <population>Pharmacokinetic (PK) evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>PRCL-02 25 Milligrams (mg)</title>
            <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
          <group group_id="O2">
            <title>PRCL-02 50 mg</title>
            <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Drug Concentration (Tmax)</title>
          <description>Steady state after 12 weeks of treatment</description>
          <population>Pharmacokinetic (PK) evaluable</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="8.12"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0" upper_limit="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRCL-02 25 Milligrams (mg)</title>
          <description>Loading dose of 150 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="E2">
          <title>PRCL-02 50 mg</title>
          <description>Loading dose of 300 mg followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
PRCL-02: Oral tablets</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
Placebo: Oral tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>medDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>medDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Recurrent psoriatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Fortier</name_or_title>
      <organization>PRCL Research Inc</organization>
      <phone>1-514-708-4417</phone>
      <email>caroline.fortier@prclresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

